CGRP Education & Research Forum
Already a member? Become a member Register

CGRP antibody therapies: real-world experience from Australia

Richard J Stark, Alfred Hospital and Monash University, Melbourne, Australia. In Australia we have had the opportunity to treat a limited number of patients with erenumab, galcanezumab and fremanezumab. Each of the companies marketing these agents has produced a scheme enabling subsidised use: patient familiarisation programmes for erenumab and fremanezumab (each limited to 10 patients …

Read more »

Real world prescribing: a view from The Netherlands

Joost Haan, Leiden University Medical Center and the Alrijne Hospital Leiderdorp, The Netherlands. In The Netherlands, erenumab, fremanezumab and galcanezumab are all available to clinicians and, as insurers do not as yet pay for these drugs, all three manufacturers run unmet need programmes through which patients with high frequency migraine can receive free treatment. Erenumab …

Read more »